What I (and Others) Told the Senate about the 340B Drug Pricing Program

Recently, a bipartisan group of six U.S. senators issued a request for information (RFI) for “input on bipartisan policy solutions that would provide stability and appropriate transparency to ensure the 340B program can continue to achieve its original intent of supporting entities serving eligible patients.” Click here to read the full letter.

I submitted a 14-page letter, which you can read below. I shared my $0.02 on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. How could I not?

Click here to read the Drug Channels Institute letter to
Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin.

Below, I include links to publicly available comments from a diverse range of stakeholders, including 340B Health, the American Hospital Association, Biotechnology Innovation Organization, Community Oncology Alliance, National Association of Community Health Centers, and Pharmaceutical Research and Manufacturers of America. Enjoy!

Here’s a representative sample of additional responses to the 340B RFI:

• 340B Health

• American Hospital Association

• Biotechnology Innovation Organization

• Community Oncology Alliance

• National Association of Community Health Centers

• PhRMA